Drug companies keeping trial info under wraps

Eli Lilly has made a point of registering all but its smallest drug trials at clinicaltrials.gov, as promised, but many other drug companies persist in holding back much of their trial information. The New York Times looks at how Merck, Pfizer, GlaxoSmithKline and other drug giants have been reluctant players in the push for more transparency in drug trials. In some cases, the companies refuse to reveal even the name of the drug under investigation. The latest push for transparency began after a series of revelations that drug companies had hidden data that raised safety questions regarding some of their most popular medications.

- read this story from The New York Times on the trials

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.